Gatifloxacin Mesylate CAS No. 316819-28-0 (DMF) Antibacterial API
02
introduce
Gatifloxacin Mesylate is water-soluble mesylate salt derivative of gatifloxacin. It inhibits bacterial DNA gyrase and topoisomerase IV with broad-spectrum bactericidal activity, suitable for oral and injectable human anti-infection pharmaceutical preparations.
Our strict quality control ensures consistent batch performance for pharmaceutical production needs.
Our strict quality control ensures consistent batch performance for pharmaceutical production needs.
02
Physical and chemical properties
Gatifloxacin Mesylate possesses key physical and chemical characteristics as follows:
- Melting Point: No standard single melting point (decomposes on heating)
- Stability: Stable under recommended low-temperature storage; avoid strong oxidants
- Storage Condition: Store at -20°C under sealed, dry and light-shielded environment
- Solubility: Freely soluble in DMSO; improved aqueous solubility compared with gatifloxacin free base
- Melting Point: No standard single melting point (decomposes on heating)
- Stability: Stable under recommended low-temperature storage; avoid strong oxidants
- Storage Condition: Store at -20°C under sealed, dry and light-shielded environment
- Solubility: Freely soluble in DMSO; improved aqueous solubility compared with gatifloxacin free base
Superior Solubility Profile
Methanesulfonate modification greatly elevates water solubility, simplifies liquid injection and oral soluble granule production without extra solubilizers.
Methanesulfonate modification greatly elevates water solubility, simplifies liquid injection and oral soluble granule production without extra solubilizers.
Full-Spectrum Antibacterial Activity
Retains potent activity against Gram-positive, Gram-negative bacteria and atypical pathogens (Mycoplasma, Chlamydia, Legionella).
Dual Target Inhibition
Blocks both DNA gyrase and topoisomerase IV to slow down bacterial resistance mutation rate. Rapid blood concentration peak after oral administration, long plasma half-life supports once-daily dosing scheme.
Mild Side Effect Risk
Lower phototoxicity and central nervous irritation side effects versus early fluoroquinolone variants.
Systemic Bacterial Infection Therapy
Treat mild-to-moderate sensitive bacterial diseases including acute sinusitis, chronic bronchitis exacerbation, community-acquired pneumonia, uncomplicated/complicated urinary tract infections, pyelonephritis and gonococcal genital infections.
Treat mild-to-moderate sensitive bacterial diseases including acute sinusitis, chronic bronchitis exacerbation, community-acquired pneumonia, uncomplicated/complicated urinary tract infections, pyelonephritis and gonococcal genital infections.
Ophthalmic Anti-Infection Drugs
Core raw material for antibacterial eye drops targeting bacterial conjunctivitis caused by Staphylococcus, Streptococcus, Haemophilus and Moraxella strains.
Injectable Antibiotic Formulations
Raw material for intravenous injection used for acute urinary tract and systemic bacterial infections with comparable efficacy to levofloxacin injections.
Laboratory Reference Standard
High-purity standard substance for fluoroquinolone pharmacology research and microbial susceptibility testing experiments.
Gatifloxacin Mesylate is a soluble salt variant of fourth-generation fluoroquinolone gatifloxacin API. Its core advantage lies in significantly improved water solubility, which expands preparation types for respiratory, urinary and ophthalmic bacterial infection treatment. It covers systemic internal medicine, ophthalmic and injectable pharmaceutical fields.
Contact our team today for sample requests, technical specifications and bulk order inquiries—we’re committed to providing efficient and customized pharmaceutical raw material solutions for you.
Contact our team today for sample requests, technical specifications and bulk order inquiries—we’re committed to providing efficient and customized pharmaceutical raw material solutions for you.